{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:43:23Z","timestamp":1788641003650,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1189975"],"award-info":[{"award-number":["1189975"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1163961"],"award-info":[{"award-number":["1163961"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11096-022-01523-3","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T20:03:36Z","timestamp":1671307416000},"page":"421-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7593-3209","authenticated-orcid":false,"given":"Louisa","family":"Picco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-1055","authenticated-orcid":false,"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"issue":"7","key":"1523_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/pds.4003","volume":"25","author":"AT Manasco","year":"2016","unstructured":"Manasco AT, Griggs C, Leeds R, et al. Characteristics of state prescription drug monitoring programs: a state-by-state survey. Pharmacoepidemiol Drug Saf. 2016;25(7):847\u201351.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"2","key":"1523_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.5811\/westjem.2017.12.35957","volume":"19","author":"JW Elder","year":"2018","unstructured":"Elder JW, DePalma G, Pines JM. Optimal implementation of prescription drug monitoring programs in the emergency department. West J Emerg Med 2018;19(2):387\u201391.","journal-title":"West J Emerg Med"},{"issue":"11","key":"1523_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/01.NPR.0000472247.21080.fc","volume":"40","author":"AJ Gudoski","year":"2015","unstructured":"Gudoski AJ. Prescription drug monitoring programs: Combating prescription drug misuse. Nurse Pract. 2015;40(11):28\u201333; quiz-4.","journal-title":"Nurse Pract."},{"issue":"9","key":"1523_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/AJP.0000000000000180","volume":"31","author":"RA Deyo","year":"2015","unstructured":"Deyo RA, Irvine JM, Hallvik SE, et al. Leading a horse to water facilitating registration and use of a prescription drug monitoring program. Clin J Pain. 2015;31(9):782\u20137.","journal-title":"Clin J Pain."},{"issue":"4","key":"1523_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3109\/15360288.2011.606292","volume":"25","author":"L Feldman","year":"2011","unstructured":"Feldman L, Williams KS, Coates J, et al. Awareness and utilization of a prescription monitoring program among physicians. J Pain Palliat Care Pharmacother. 2011;25(4):313\u20137.","journal-title":"J Pain Palliat Care Pharmacother."},{"issue":"4","key":"1523_CR6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/pm\/pnz289","volume":"21","author":"GL Mastarone","year":"2019","unstructured":"Mastarone GL, Wyse JJ, Wilbur ER, et al. Barriers to Utilization of Prescription Drug Monitoring Programs Among Prescribing Physicians and Advanced Practice Registered Nurses at Veterans Health Administration Facilities in Oregon. Pain Med. 2019;21(4):695\u2013703.","journal-title":"Pain Med."},{"issue":"1","key":"1523_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10826084.2019.1648512","volume":"55","author":"J Reist","year":"2019","unstructured":"Reist J, Frazier J, Rottingham A, et al. Provider beliefs on the Barriers and Facilitators to Prescription Monitoring Programs and Mandated Use. Subst Use Misuse. 2019:1\u201311.","journal-title":"Subst Use Misuse."},{"issue":"3","key":"1523_CR8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.sapharm.2015.07.008","volume":"12","author":"CW Norwood","year":"2016","unstructured":"Norwood CW, Wright ER. Promoting consistent use of prescription drug monitoring programs (PDMP) in outpatient pharmacies: Removing administrative barriers and increasing awareness of Rx drug abuse. Res Soc Adm Pharm. 2016;12(3):509\u201314.","journal-title":"Res. Social Adm. Pharm."},{"issue":"6","key":"1523_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/pme.12700","volume":"16","author":"RJ Smith","year":"2015","unstructured":"Smith RJ, Kilaru AS, Perrone J, et al. How, why, and for whom do emergency medicine providers use prescription drug monitoring programs? Pain Med. 2015;16.","journal-title":"Pain Med."},{"key":"1523_CR10","unstructured":"Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC). Mandatory Enrollment and Use of PDMPs. USA: Prescription Drug Monitoring Program Training and Technical Assistance Center; 2020."},{"issue":"12","key":"1523_CR11","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2105\/AJPH.2018.304704","volume":"108","author":"A Shev","year":"2018","unstructured":"Shev A, Wintemute G, Cerd\u00e1 M, et al. Prescription drug monitoring program: Registration and use by prescribers and pharmacists before and after legal mandatory registration, california, 2010\u20132017. Am J Public Health. 2018;108(12):1669\u201374.","journal-title":"Am J Public Health."},{"issue":"2","key":"1523_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.18773\/austprescr.2019.007","volume":"42","author":"P Boyles","year":"2019","unstructured":"Boyles P. Real-time prescription monitoring: lessons from Tasmania. Aust Prescr. 2019;42(2):48\u20139.","journal-title":"Aust. Prescr."},{"key":"1523_CR13","unstructured":"Department of Health. National Real Time Prescription Monitoring (RTPM) Canberra: Australian Government; 2022 [Available from: https:\/\/www.health.gov.au\/initiatives-and-programs\/national-real-time-prescription-monitoring-rtpm. Accessed 23 May 2022."},{"key":"1523_CR14","unstructured":"Australian Bureau of Statistics. National, state and territory population Canberra: Australian Bureau of Statistics, 2020 [Available from: https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/latest-release. Accessed 18 May 2021."},{"key":"1523_CR15","unstructured":"Victorian Department of Health and Human Services. SafeScript FAQs for health professionals Victoria2019 [Available from: https:\/\/www2.health.vic.gov.au\/public-health\/drugs-and-poisons\/safescript\/health-professionals. Accessed 10 Jan 2022."},{"key":"1523_CR16","unstructured":"Department of Health (Victoria). SafeScript: For prescribers and pharmacists Melbourne: Department of Health (Victoria); 2021 [Available from: https:\/\/www.health.vic.gov.au\/drugs-and-poisons\/for-prescribers-and-pharmacists. Accessed 11 Jan 2022."},{"key":"1523_CR17","unstructured":"Maven Marketing. List of Pharmacies and Chemists in Australia. 2019 [Available from: http:\/\/www.mavenmarketing.com.au\/list-of-pharmacies-in-australia\/. Accessed 18 Mar 2021."},{"key":"1523_CR18","unstructured":"Core List. Pharmacies in Australia. 2020 [Available from: https:\/\/corelist.com.au\/pharmacies-in-australia\/. Accessed 24 Mar 2021."},{"key":"1523_CR19","unstructured":"Department of Health. Modified Monash Model. 2019 [Available from https:\/\/www.health.gov.au\/topics\/rural-health-workforce\/classifications\/mmm#about-the-modified-monash-model. Accessed 11 Jan 2022"},{"key":"1523_CR20","first-page":"Mr000008","volume":"3","author":"PJ Edwards","year":"2009","unstructured":"Edwards PJ, Roberts I, Clarke MJ, et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev. 2009(3):Mr000008.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"1523_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.japh.2019.09.016","volume":"60","author":"RG Pett","year":"2020","unstructured":"Pett RG, Mancl L, Revere D, et al. Prescription drug monitoring program use and utility by Washington State pharmacists: A mixed-methods study. J Am Pharm Assoc. 2020;60(1):57\u201365","journal-title":"J Am Pharm Assoc."},{"issue":"4","key":"1523_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.japh.2021.02.020","volume":"61","author":"NM Rickles","year":"2021","unstructured":"Rickles NM, Wakai S, Karim-Nejad L. The use of an integrated opioid and medical marijuana prescription drug monitoring program. J Am Pharm Assoc. 2021;61(4):408\u201317","journal-title":"J Am Pharm Assoc."},{"issue":"2","key":"1523_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11096-020-01074-5","volume":"43","author":"S Nielsen","year":"2021","unstructured":"Nielsen S, Sanfilippo P, Picco L, et al. What predicts pharmacists\u2019 engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy. Int J Clin Pharm. 2021;43(2):420\u20139.","journal-title":"Int. J. Clin. Pharm."},{"issue":"12","key":"1523_CR24","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1111\/add.13517","volume":"111","author":"S Nielsen","year":"2016","unstructured":"Nielsen S, Menon N, Larney S, et al. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. Addiction. 2016;111(12):2177\u201386.","journal-title":"Addiction."},{"issue":"1","key":"1523_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1525\/jer.2006.1.1.9","volume":"1","author":"G Willis","year":"2006","unstructured":"Willis G. Cognitive Interviewing as a Tool for Improving the Informed Consent Process. J Empir Res Hum Res Ethics. 2006;1(1):9\u201323.","journal-title":"J Empir Res Hum Res Ethics."},{"issue":"2","key":"1523_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5127\/jep.008310","volume":"2","author":"J Decoster","year":"2011","unstructured":"DeCoster J, Gallucci M, Iselin A-MR. Best practices for using median splits, artificial categorization, and their continuous alternatives. J Exp Psychopathol. 2011;2(2):197\u2013209.","journal-title":"J Exp Psychopathol."},{"issue":"5","key":"1523_CR27","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.japh.2018.06.003","volume":"58","author":"K Johnston","year":"2018","unstructured":"Johnston K, Alley L, Novak K, et al. Pharmacists' attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: A brief scoping review. J Am Pharm Assoc. 2018;58(5):568\u201376.","journal-title":"J Am Pharm Assoc."},{"key":"1523_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.drugalcdep.2017.08.040","volume":"180","author":"L Rutkow","year":"2017","unstructured":"Rutkow L, Smith KC, Lai AY, et al. Prescription drug monitoring program design and function: a qualitative analysis. Drug Alcohol Depend. 2017;180:395\u2013400.","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"1523_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1331\/JAPhA.2013.12094","volume":"53","author":"TC Green","year":"2013","unstructured":"Green TC, Mann MR, Bowman SE, et al. How does use of a prescription monitoring program change pharmacy practice? J Am Pharm Assoc. 2013;53(3):273\u201381.","journal-title":"J Am Pharm Assoc."},{"issue":"6","key":"1523_CR30","first-page":"1063","volume":"18","author":"GJ Leichtling","year":"2017","unstructured":"Leichtling GJ, Irvine JM, Hildebran C, et al. Clinicians' use of prescription drug monitoring programs in clinical practice and decision-making. Pain Med. 2017;18(6):1063\u20139.","journal-title":"Pain Med."},{"issue":"2","key":"1523_CR31","first-page":"2214","volume":"13","author":"JD Smith","year":"2013","unstructured":"Smith JD, White C, Roufeil L, et al. A national study into the rural and remote pharmacist workforce. Rural Remote Health. 2013;13(2):2214.","journal-title":"Rural Remote Health."},{"key":"1523_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/JMDH.S236488","volume":"13","author":"CA Hays","year":"2020","unstructured":"Hays CA, Taylor SM, Glass BD. The Rural Pharmacy Practice Landscape: Challenges and Motivators. J Multidiscip Healthc. 2020;13:227\u201334.","journal-title":"J Multidiscip Healthc."},{"issue":"5","key":"1523_CR33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1440-1584.2006.00812.x","volume":"14","author":"A Harding","year":"2006","unstructured":"Harding A, Whitehead P, Aslani P, et al. Factors affecting the recruitment and retention of pharmacists to practice sites in rural and remote areas of New South Wales: a qualitative study. Aust J Rural Health. 2006;14(5):214\u20138.","journal-title":"Aust J Rural Health."},{"key":"1523_CR34","unstructured":"Penington Institute. Australia\u2019s Annual Overdose Report 2021. Melbourne: Penington Institute 2021."},{"issue":"4","key":"1523_CR35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.sapharm.2018.06.013","volume":"15","author":"TJ Schindel","year":"2019","unstructured":"Schindel TJ, Yuksel N, Breault R, et al. Pharmacists' learning needs in the era of expanding scopes of practice: Evolving practices and changing needs. Res Social Adm Pharm. 2019;15(4):448\u201358.","journal-title":"Res Soc Adm Pharm."},{"key":"1523_CR36","doi-asserted-by":"publisher","first-page":"109090","DOI":"10.1016\/j.drugalcdep.2021.109090","volume":"228","author":"L Picco","year":"2021","unstructured":"Picco L, Lam T, Haines S, et al. How prescription drug monitoring programs inform clinical decision-making: A mixed methods systematic review. Drug Alcohol Depend. 2021;228:1009090.","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"1523_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1037\/0021-9010.88.2.234","volume":"88","author":"W Arthur","year":"2003","unstructured":"Arthur W, Bennett W, Edens P, et al. Effectiveness of training in organizations: a meta-analysis of design and evaluation features. J Appl Psychol. 2003;88(2):234\u201345.","journal-title":"J Appl Psychol."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01523-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-022-01523-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-022-01523-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:30:40Z","timestamp":1744209040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-022-01523-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1523"],"URL":"https:\/\/doi.org\/10.1007\/s11096-022-01523-3","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]},"assertion":[{"value":"31 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No authors have conflicts to declare related to the current research study. SN has received unrelated research funding from Indivior and Seqirus, and her institution has received honoraria for training delivered on codeine dependence from Indivior. TL has been an investigator on untied education grants from Seqirus.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}